I want to be clear about something before we get into the data: I'm not a doctor. I'm a 52-year-old former operations director who spent 25 years optimizing systems for Fortune 500 companies. Three years ago I started applying that same discipline to my own biology.

This is my research journal. These are my observations. None of this is medical advice and none of it should be interpreted as a recommendation for anyone else's protocol.

Why I Started Researching SPR-2TR

At 52, the things I used to take for granted started requiring effort. Verbal recall during high-stakes board meetings. Sustaining focus across 10-hour days. Recovery from international travel. My Oura ring data showed HRV declining steadily over 18 months.

I spent six months reading published in vitro research on various peptide compounds before I felt confident enough to design a tracking protocol. SPR-2TR came up repeatedly in the receptor binding literature. I was interested in the cellular signaling pathway data specifically.

The Verification Process

Before sourcing anything I required a third-party COA. Not an internal COA — a verified external lab result I could check myself. This is non-negotiable for me.

I source exclusively through Solara Peptide Research because they use Accumark verification — an independent authentication system where I can verify the exact batch COA online before it arrives. Their SPR-2TR showed 99.958% purity on HPLC/MS testing. That's the standard I require.

My 90-Day Tracking Data

I tracked six variables across 90 days. Here's the summary table:

I want to be careful here. I changed nothing else during these 90 days by design — same sleep schedule, same diet, same exercise protocol. However, I cannot rule out confounding variables. This is n=1 observational tracking, not a controlled study.

What the In Vitro Literature Says

What makes SPR-2TR interesting from a research standpoint is the receptor binding kinetics data in cell culture models. The published literature on similar peptide structures shows interaction with cellular signaling pathways involved in mitochondrial function and neuroprotective gene expression — in vitro.

I am not drawing a direct line between that research and my own tracking data. I'm documenting observations alongside the science so other researchers can draw their own conclusions.

Final Observations

After 90 days of documentation I have enough data to continue the protocol through Q4. The data trends are interesting enough to warrant continued tracking. I've ordered the next batch from Solara — same batch verification process, same documentation standard.

If you're designing a similar research protocol, the most important thing I can tell you is to establish your baseline before you start. Data without a baseline is noise.

I've been dealing with bilateral patellar tendinopathy for three years. Two rounds of PRP, one platelet-poor plasma protocol, physical therapy for 14 months. I kept training through it because stopping wasn't an option, but load tolerance was a constant ceiling.

I started researching peptide compounds that showed up in the connective tissue repair literature. SPR-3RT appeared in cell culture studies examining fibroblast activity and extracellular matrix remodeling. I wanted to document my own tracking data alongside that science.

Verification First

I source only from Solara Peptide Research. Their SPR-3RT batch (Accumark verified, 99.908% HPLC purity) was the only one I found with independent verification I could check before receiving. That matters to me. I'm not putting anything near my research protocol that I can't trace to a third-party lab result.

8-Week Tracking Summary

Again — n=1, observational, multiple variables changed (including programming adjustments). I'm not making causation claims. I'm documenting what I tracked.

I spent 12 years in biochemistry research. When I left academic medicine I didn't stop being curious — I redirected that curiosity toward my own biology. GHK-Cu (glycine-histidine-lysine copper complex) has an extraordinary body of in vitro research behind it, particularly around collagen synthesis stimulation and matrix metalloproteinase regulation in cell culture models.

I designed a 12-week tracking protocol with monthly photo documentation, TEWL measurements, and a standardized dermatology assessment scale.

Sourcing Standards

As a biochemist I was particularly rigorous here. I required HPLC/MS third-party verification with a batch number I could independently confirm. Solara Peptide Research was the only vendor I found with Accumark verification — an authentication system where I could verify the exact COA before receiving the compound. That's the standard I hold in a lab environment. It's the standard I hold for my own research.

12-Week Tracking Results

I had a colleague conduct monthly blinded evaluations using standardized photography. I was blinded to her scores until week 12. The correlation between objective measurements and blinded evaluation was 0.89 — which I found meaningful as a data validation point.